Taysha Gene Therapies (NASDAQ:TSHA) Now Covered by BMO Capital Markets

BMO Capital Markets began coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note published on Thursday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $5.00 target price on the stock.

A number of other brokerages have also weighed in on TSHA. Needham & Company LLC reaffirmed a buy rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday, June 17th. JMP Securities reaffirmed a market outperform rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Piper Sandler initiated coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price for the company. Canaccord Genuity Group reaffirmed a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Finally, Jefferies Financial Group reissued a buy rating and set a $8.00 price objective (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of Buy and a consensus price target of $6.80.

Taysha Gene Therapies Stock Performance

NASDAQ:TSHA opened at $2.17 on Thursday. Taysha Gene Therapies has a 12-month low of $0.57 and a 12-month high of $4.32. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.38 and a quick ratio of 3.38. The stock’s 50 day simple moving average is $2.97 and its 200-day simple moving average is $2.41.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the firm earned ($0.28) EPS. As a group, analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Howard Capital Management Inc. purchased a new position in Taysha Gene Therapies during the fourth quarter worth $25,000. Victory Capital Management Inc. purchased a new stake in Taysha Gene Therapies during the 4th quarter worth about $28,000. Dynamic Technology Lab Private Ltd acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $38,000. Finally, Cannon Global Investment Management LLC purchased a new position in Taysha Gene Therapies in the 1st quarter valued at about $69,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.